Each week we highlight five things affecting the life sciences industry. Here’s the latest.
Policy could cast doubt on U.S.-China biotech collaborations
- The America First investment policy could introduce uncertainty in the thriving U.S.-China biotech sector, hindering cross-border collaborations.
- While disruptions to biotech licensing deals are unlikely, the policy may affect future investments and partnerships between U.S. and Chinese biotech firms, according to Fierce Pharma.
Federal judge blocks grant funding cuts
- A U.S. federal judge has issued a nationwide injunction preventing the administration from implementing significant reductions to National Institutes of Health research grants.
- Fierce Biotech reports that the proposed cuts aimed to cap indirect cost reimbursements at 15%, potentially saving the government $4 billion annually, but faced legal challenges from 22 states and numerous research institutions.
Major cancer drug subject to patent dispute
- The Wall Street Journal reports that Merck is facing a patent dispute with a biotech company over an enzyme used in a new injectable version of its top-selling oncology drug, Keytruda. Merck claims it developed the enzyme independently, while the counterparty argues that the new Keytruda infringes on its patents and requires a licensing agreement.
- With Keytruda’s U.S. patent expiring in 2028, Merck aims to shift from the current intravenous version to an injectable option to maintain market dominance and counter competition from generics.
European biopharma nearshoring strategies
- European biopharma manufacturers are increasingly considering nearshoring—relocating production closer to home—to enhance supply chain resilience and reduce dependency on distant markets.
- This shift is driven by factors such as supply chain disruptions, geopolitical tensions and the desire for greater control over manufacturing processes, reports Pharmaceutical Technology.
Importance of data governance in pharma’s AI integration
- Forbes reports that effective data governance is crucial for pharmaceutical companies to harness artificial intelligence’s potential, ensuring data quality, compliance and ethical standards.
- Implementing robust data strategies enhances AI-driven drug development, leading to more efficient and accurate outcomes.
For more insights in life sciences, check out RSM’s industry outlook.
